Literature DB >> 30882253

What should we tackle next in acute myeloid leukemia? Wilms tumor gene 1 vaccine therapy would be a promising and versatile strategy for acute myeloid leukemia.

Jun Nakata1, Yusuke Oji2, Yoshihiro Oka3, Haruo Sugiyama4.   

Abstract

Entities:  

Keywords:  Acute myeloid leukemia (AML); WT1 vaccine therapy; Wilms tumor 1 (WT1); cancer immunotherapy; cancer vaccine

Mesh：

Substances：

Year:  2019        PMID： 30882253     DOI： 10.1080/17474086.2019.1593824

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN： 1747-4094            Impact factor:   2.929


× No keyword cloud information.
  2 in total

1.  Human CLEC9A antibodies deliver Wilms' tumor 1 (WT1) antigen to CD141+ dendritic cells to activate naïve and memory WT1-specific CD8+ T cells.

Authors:  Frances E Pearson; Kirsteen M Tullett; Ingrid M Leal-Rojas; Oscar L Haigh; Kelly-Anne Masterman; Carina Walpole; John S Bridgeman; James E McLaren; Kristin Ladell; Kelly Miners; Sian Llewellyn-Lacey; David A Price; Antje Tunger; Marc Schmitz; John J Miles; Mireille H Lahoud; Kristen J Radford
Journal:  Clin Transl Immunology       Date:  2020-06-12

2.  Clinical Grade Production of Wilms' Tumor-1 Loaded Cord Blood-Derived Dendritic Cells to Prevent Relapse in Pediatric AML After Cord Blood Transplantation.

Authors:  Maud Plantinga; Vania Lo Presti; Colin G de Haar; Ester Dünnebach; Alejandro Madrigal; Caroline A Lindemans; Jaap Jan Boelens; Stefan Nierkens
Journal:  Front Immunol       Date:  2020-09-25       Impact factor: 7.561
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.